These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 6774066)

  • 1. Preparation and biological distribution of technetium diphosphonate radiotracers synthesized without stannous ion.
    Deutsch E; Libson K; Becker CB; Francis MD; Tofe AJ; Ferguson DL; McCreary LD
    J Nucl Med; 1980 Sep; 21(9):859-66. PubMed ID: 6774066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo behaviour of four different 99(m)Tc-HEDP complexes.
    Inoue O; Yamaguchi T; Ikeda I
    Nuklearmedizin; 1982 Dec; 21(6):227-31. PubMed ID: 6820139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of two different HEDP content kits: stability study against dilution both in vivo and in vitro.
    Inoue O; Ikeda I; Kurata K
    Nuklearmedizin; 1982 Jun; 21(3):121-5. PubMed ID: 6813826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo labeling of red blood cells with Tc-99m with stannous pyridoxylideneaminates.
    Kato M
    J Nucl Med; 1979 Oct; 20(10):1071-4. PubMed ID: 536758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of reaction conditions on preparations of rhenium-188 hydroxyethylidene diphosphonate complexes.
    Lin WY; Hsieh JF; Lin CP; Hsieh BT; Ting G; Wang SJ; Knapp FF
    Nucl Med Biol; 1999 May; 26(4):455-9. PubMed ID: 10382850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technetium-99m radiopharmaceutical preparation by surface adsorbed stannous ions.
    Salehi N; Lichtenstein M; Pojer PM
    J Nucl Med; 1987 Jun; 28(6):1041-6. PubMed ID: 3675734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro stabilization of a low-tin bone-imaging agent (99mTc-Sn-HEDP) by ascorbic acid.
    Tofe AJ; Francis MD
    J Nucl Med; 1976 Sep; 17(9):820-5. PubMed ID: 822138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo distribution of Tc-99m(Sn)pyridoxylideneisoleucine: effects of storage and labeling conditions. Concise communication.
    Kato M
    J Nucl Med; 1979 Nov; 20(11):1189-93. PubMed ID: 536780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 99mTc-labelled compounds prepared with sodium dithionite as reducing agent.
    Vilcek S; Kalincák M; Machán V
    Nuklearmedizin; 1981 Dec; 20(6):283-9. PubMed ID: 6460222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexing of reduced technetium and tin(II) by chelating phosphate compounds. II. In vitro stability of pyrophosphate and ethane-1, hydroxy-1, diphosphonate (EHDP) complexes.
    Schümichen C; Hohloch M; Hoffmann G
    Nuklearmedizin; 1979 May; 18(2):105-9. PubMed ID: 38437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical problems associated with the production of technetium Tc 99m tin(II) pyrophosphate kits.
    Kowalsky RJ; Dalton DR
    Am J Hosp Pharm; 1981 Nov; 38(11):1722-6. PubMed ID: 7304626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexes of technetium with pyrophosphate, etidronate, and medronate.
    Russell CD; Cash AG
    J Nucl Med; 1979 Jun; 20(6):532-7. PubMed ID: 43885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of two new [99mTc]Tc-HEDP preparations that can be expected to give a better lesion-to-normal-bone uptake ratio when used as bone scanning agents.
    de Ligny CL; Gelsema WJ; Hoevelaken TP; Schuring J
    Nucl Med Biol; 1993 Jan; 20(1):23-9. PubMed ID: 8461877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of techniques for rapid and efficient in vivo labeling of red cells with [99mTc] pertechnetate.
    Hamilton RG; Alderson PO
    J Nucl Med; 1977 Oct; 18(10):1010-3. PubMed ID: 903468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Technetium-99m labeled agents for skeletal imaging.
    Thrall JH
    CRC Crit Rev Clin Radiol Nucl Med; 1976; 8(1):1-31. PubMed ID: 789010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. I. Synthesis and distribution in animals.
    Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
    J Nucl Med; 1980 Oct; 21(10):961-6. PubMed ID: 6252298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tc-99m HMDP (hydroxymethylene diphosphonate): a radiopharmaceutical for skeletal and acute myocardial infarct imaging. II. Comparison of Tc-99m hydroxymethylene diphosphonate (HMDP) with other technetium-labeled bone-imaging agents in a canine model.
    Bevan JA; Tofe AJ; Benedict JJ; Francis MD; Barnett BL
    J Nucl Med; 1980 Oct; 21(10):967-70. PubMed ID: 6252299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukocyte labeling with technetium-99m tin colloids.
    Mock BH; English D
    J Nucl Med; 1987 Sep; 28(9):1471-7. PubMed ID: 3625299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurements of the distribution of technetium-99m sulfur colloid and technetium-99m HEDP in normal humans.
    Grossman LW; Sodd VJ; Nishiyama H; Feller PA; Hoops RG
    Med Phys; 1983; 10(1):79-82. PubMed ID: 6405144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
    Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
    J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.